Top Tech Companies (32)
Mayne Pharma is an ASX-listed specialty pharmaceutical Company (ASX: MYX) focused on commercializing novel and generic pharmaceuticals. We offer patients better, safe and more accessible medicines. Mayne Pharma has a 40-year track record of innovation and success in developing oral drug delivery systems. These technologies have been successfully commercialized in numerous products that continue to be marketed around the world. Mayne Pharma also has a full service contract development and manufacturing organizations (CDMO) servicing clients worldwide: Mayne Contract Services is based in Salisbury, SA, Australia Here are some key facts about our company: • 400+ staff • A$500m+ market cap • A$400m+ in revenue (FY22) • A product portfolio of 90+ marketed products globally The Company's corporate values are: • Empowerment – encouraging everyone to take initiative, enabling growth and achievement. • Passion – showing pride, enthusiasm and dedication in everything we do. • Creativity – delivering value and striving to connect new ideas with business realities. • Agility – operating with timeliness as well as mental, emotional and physical flexibility. • Integrity – maintaining high ethical standards, demonstrating honesty, and respecting fairness by doing the right thing, even when no one is looking. • Accountability – accepting our individual and team responsibilities, meeting our commitments, and acknowledging and learning from mistakes. To learn more, visit us at www.maynepharma.com. Our social media policy: https://bit.ly/3py3L1e Any communication you receive from Mayne Pharma will never come from a personal email domain or chat service such as "gmail" or "Google Chat". All official communication from Mayne Pharma will be received from our company email domain - @maynepharma.com.
Halaxy makes healthcare better all over the world. Halaxy is a platform for patients, practitioners and people everywhere, and provides: 1. Practice management software (EMR, billing and scheduling) for any practitioner of any profession in any practice anywhere in the world; 2. Searchable practitioner directories covering 50% of the English speaking world enabling people to find the right practitioner for them; 3. Clinical tools to track your health for people to improve their health, manage conditions and bring together all their health information in the one place; and 4. Personally controlled shared health records. Halaxy is also a leader in telehealth and online consultations platforms, and health informatics. Halaxy solves the underlying issues of healthcare to make healthcare efficient, effective and accessible wherever you are in the world.
Palla Pharma Limited is one of three licensed poppy processors in Australia, and the only Australian-owned company. It is one of only three companies globally that is vertically integrated from poppy growing through to tableting production. Palla Pharma has developed an innovative, efficient and environmentally-sustainable extraction and purification manufacturing process which allows the company to deliver a highly competitive pricing platform. The company’s strategy is to secure access to regulated downstream narcotics markets to leverage its reliable, cost-competitive upstream raw material capability.
Mesoblast (ASX:MSB; Nasdaq:MESO) is developing and commercializing allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases with significant, unmet medical needs. The Company's Phase 3 off-the-shelf mesenchymal lineage cell product candidates are: • RYONCIL™ (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD) • Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection • REVASCOR® for advanced chronic heart failure, and • MPC-06-ID for chronic low back pain due to degenerative disc disease. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast’s approach to product development is to ensure rigorous scientific investigations are performed with well-characterized cell populations in order to understand mechanisms of action for each potential indication. Extensive preclinical translational studies guide clinical trials that are structured to meet stringent safety and efficacy criteria set by international regulatory agencies. All trials are conducted under the continuing review of independent Data Safety Monitoring Boards comprised of independent medical experts and statisticians. Mesoblast has an extensive patent portfolio comprising approximately 1,000 patents and patent applications with protection extending through 2040 in all major markets. This intellectual property portfolio covers composition of matter, manufacturing, and therapeutic applications of mesenchymal lineage cells. The Company believes this patent estate provides strong global protection.
Nanochap is a fabless semiconductor company with its core R&D team based in Melbourne, Australia. We specialise in neural interface and biosensing SoCs. The company is committed to the R&D, design, packaging, testing, and commercialisation of ultra-high density neural interface chips, biosensing chips, and other medical device related chips.
Montu is Australia's leading health tech business revolutionising the alternative health landscape. Montu has built an integrated ecosystem, which streamlines the experience for patients end-to-end, and sets new standards. The company is committed to improve the lives of millions of patients
Profound Change Requires Boldness. Johnson & Johnson is the largest and most broadly based healthcare company in the world. We’re producing life-changing breakthroughs every day, and have been for the last 130 years. The combination of new technologies and your expertise enables amazing things to happen. Teams from J&J’s consumer business are creating digital tools to help people track the health of their skin. Those working in medical devices are 3-D printing artificial joints personalized for each patient, while researchers in pharmaceuticals use AI to discover lifesaving drugs. Imagine what the rest of our team of 134,000 people at 260 companies in more than 60 countries across the world is accomplishing. We redefine what it means to be a big company in today’s world. Social Media Community Guidelines: http://www.jnj.com/social-media-community-guidelines
Welcome to Cabrini Health Cabrini is owned and operated by the Missionary Sisters of the Sacred Heart of Jesus who came to Australia in 1948 to take over the management of a 45-bed community hospital named St Benedict’s. Cabrini now has more than 800 beds and a comprehensive range of health services. There are acute facilities at Malvern and Brighton. The Cabrini Institute supports education and research, in order to continually improve the quality of care and educate tomorrow’s health professionals. Cabrini Technology provides an innovative, independent information and healthcare technology service to organisations throughout Australasia and has headquarters in Mount Waverley. More recently, Cabrini has established an Asylum Seeker and Refugee Health Hub in Brunswick, which provides access to a range of health services for people seeking asylum and newly arrived refugees. Cabrini is a not-for-profit health service and all surpluses are used to develop our services and facilities to provide the best possible care for patients and families. Cabrini supports and operates a number of other programs for disadvantaged people in our community. Patient care is the primary focus of our work and at the heart of all we do
CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY; XETRA-DAX: UR9) is a global and diversified biopharmaceutical company focused on developing and commercialising treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. As pioneers in photomedicine and understanding the interaction of light and human biology, CLINUVEL’s research and development has led to innovative treatments for patient populations with a clinical need for systemic photoprotection, DNA repair and acute or life threatening conditions. These patient groups range in size from 5,000 to 45 million worldwide. CLINUVEL’s lead compound, SCENESSE® (afamelanotide 16mg), was approved by the European Commission in 2014 and the US Food and Drug Administration in 2019 for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). More information on EPP can be found at http://www.epp.care. Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Singapore, and the USA. For more information please go to http://www.clinuvel.com. SCENESSE® and PRÉNUMBRA® are registered trademarks of CLINUVEL PHARMACEUTICALS LTD
Aravax is a clinical stage biotechnology company developing a novel peptide-based immunotherapy, PVX108, for the treatment of peanut allergy. Aravax is striving to improve the lives of patients living with peanut allergies by developing a therapy that precisely targets the underlying cause of disease, bringing benefits in safety and convenience.
Advancing the world’s transition to AI-supported healthcare.
At See-Mode, our mission is to unlock the hidden insights in medical imaging with AI, and empower clinicians to improve patient outcomes. Our AI-enhanced ultrasound reporting software automatically reads and assesses ultrasound images, producing accurate clinical reports.
